News

The company expects to launch the Kit in July 2008. The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues. Xiaodong Wu, chairman

Merck has the first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine. Stanley Erck, president and CEO of

This independent, investigator-initiated study is being sponsored by Tatsuro Kamakura, chief medical officer of Cosmetic Surgery Seishin, in Japan. Results of the study will be available following a

PVI is a dynamic new indicator of fluid responsiveness that does not require an invasive procedure or manual calculation, yet has been demonstrated to be sensitive to changes

The recombinant adenovirus serotype 26 (rAd26) vector is specifically designed to avoid the pre-existing immunity to the more commonly used adenovirus serotype 5 (Ad5), which has recently shown

These contracts with a pharmaceutical company (the sponsor) are part of a series of seven contracts related to clinical trials that form part of a global development program

Results from this 28 week randomized, double-blind, placebo-controlled, multi-center pivotal study will be presented during the fourth quarter of 2008 and be used to file for licensure in

Asuragen is transferring its microRNA’s (miRNA) therapeutic intellectual property to Mirna Therapeutics and seeding the new company with $3 million in capital. miRNAs are naturally occurring small RNAs

Under the terms of the agreement, Akorn will be responsible for development, marketing and distribution of the premix product. Fresenius Kabi will manufacture the product at its intravenous